Joni A Turunen1, Salla Markkinen2, Rosi Wilska3, Silva Saarinen4, Virpi Raivio3, Martin Täll3, Anna-Elina Lehesjoki5, Tero T Kivelä3. 1. Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Folkhälsan Institute of Genetics, Helsinki, Finland. Electronic address: joni.turunen@helsinki.fi. 2. Folkhälsan Institute of Genetics, Helsinki, Finland. 3. Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 4. Department of Medical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. 5. Folkhälsan Institute of Genetics, Helsinki, Finland; Neuroscience Center and Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland.
Abstract
PURPOSE: Germline mutations of the BRCA1-associated protein-1 gene (BAP1) predispose carriers to uveal melanoma. We report the population-based frequency of germline pathogenic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this cancer. DESIGN: Cohort study. PARTICIPANTS: In Finland, uveal melanomas are treated centrally in the Ocular Oncology Service, Helsinki University Hospital. We collected clinical data and genomic DNA from 148 of 188 consecutive patients diagnosed from January 2010 through December 2012. Seven of these patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 additional families had such a history in 2 relatives. METHODS: Sequencing BAP1. MAIN OUTCOME MEASURES: Pathogenic variants in BAP1. RESULTS: We found 2 different pathogenic variants in BAP1 in 3 patients. Two patients had a single nucleotide insertion in exon 14 resulting in a shift of reading frame. Both had a family history of uveal melanoma in at least 1 relative. One patient without a family history of uveal melanoma had a single nucleotide substitution in the conserved splice donor site of intron 2. BAP1 cancer predisposition syndrome-related cancers were present in all 3 families. The overall frequency of BAP1 pathogenic variants was 2.0% (3/148; 95% confidence interval, 0.4-5.8), the frequency among patients 50 years of age or younger was 3.6% (1/28; 95% confidence interval, 0.1-18), and a pathogenic variant was detected in 2 of 8 families with a history of uveal melanoma. CONCLUSIONS: The frequency of BAP1 germline pathogenic variants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the development of this cancer is comparable with reports from other populations.
PURPOSE: Germline mutations of the BRCA1-associated protein-1 gene (BAP1) predispose carriers to uveal melanoma. We report the population-based frequency of germline pathogenic variants of BAP1 in Finnish patients with uveal melanoma who live in a high-risk region for this cancer. DESIGN: Cohort study. PARTICIPANTS: In Finland, uveal melanomas are treated centrally in the Ocular Oncology Service, Helsinki University Hospital. We collected clinical data and genomic DNA from 148 of 188 consecutive patients diagnosed from January 2010 through December 2012. Seven of these patients from 6 families had a history of uveal melanoma in 1 relative, and 2 patients from 2 additional families had such a history in 2 relatives. METHODS: Sequencing BAP1. MAIN OUTCOME MEASURES: Pathogenic variants in BAP1. RESULTS: We found 2 different pathogenic variants in BAP1 in 3 patients. Two patients had a single nucleotide insertion in exon 14 resulting in a shift of reading frame. Both had a family history of uveal melanoma in at least 1 relative. One patient without a family history of uveal melanoma had a single nucleotide substitution in the conserved splice donor site of intron 2. BAP1cancer predisposition syndrome-related cancers were present in all 3 families. The overall frequency of BAP1 pathogenic variants was 2.0% (3/148; 95% confidence interval, 0.4-5.8), the frequency among patients 50 years of age or younger was 3.6% (1/28; 95% confidence interval, 0.1-18), and a pathogenic variant was detected in 2 of 8 families with a history of uveal melanoma. CONCLUSIONS: The frequency of BAP1 germline pathogenic variants in consecutive Finnish patients with uveal melanoma who come from a high-risk region for the development of this cancer is comparable with reports from other populations.
Authors: Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Getachew Boru; Timothy W Grosel; Robert Pilarski; Meredith Stautberg; James B Massengill; Joanne Jeter; Arun Singh; Meghan J Marino; Joseph P McElroy; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman Journal: Genes Chromosomes Cancer Date: 2019-04-23 Impact factor: 5.006
Authors: Marjorie G Zauderer; Gowtham Jayakumaran; Mariel DuBoff; Liying Zhang; Jasmine H Francis; David H Abramson; Andrea Cercek; Garrett M Nash; Alexander Shoushtari; Paul Chapman; Sandra D'Angelo; Angela G Arnold; Beth Siegel; Megan Harlan Fleischut; Andy Ni; Andreas Rimner; Valerie W Rusch; Prasad S Adusumilli; William Travis; Jennifer L Sauter; Ahmet Zehir; Diana Mandelker; Marc Ladanyi; Mark Robson Journal: J Thorac Oncol Date: 2019-07-16 Impact factor: 15.609
Authors: Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami Journal: JAMA Dermatol Date: 2017-10-01 Impact factor: 10.282
Authors: Karan Rai; Robert Pilarski; Getachew Boru; Muneeb Rehman; Ahmad H Saqr; James B Massengill; Arun Singh; Meghan J Marino; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman Journal: Genes Chromosomes Cancer Date: 2016-10-26 Impact factor: 5.006
Authors: Mohamed H Abdel-Rahman; Klarke M Sample; Robert Pilarski; Tomas Walsh; Timothy Grosel; Daniel Kinnamon; Getachew Boru; James B Massengill; Lynn Schoenfield; Ben Kelly; David Gordon; Peter Johansson; Meghan J DeBenedictis; Arun Singh; Silvia Casadei; Frederick H Davidorf; Peter White; Andrew W Stacey; James Scarth; Ellie Fewings; Marc Tischkowitz; Mary-Claire King; Nicholas K Hayward; Colleen M Cebulla Journal: Ophthalmology Date: 2019-11-18 Impact factor: 12.079
Authors: Nakul Singh; Rahul Singh; Randy Chris Bowen; Mohamed H Abdel-Rahman; Arun D Singh Journal: Am J Ophthalmol Date: 2020-12-11 Impact factor: 5.258
Authors: Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino Journal: Cancer Discov Date: 2020-07-20 Impact factor: 38.272